论文部分内容阅读
目的观察血脂康短期治疗对胆固醇水平正常的慢性心力衰患者血清肿瘤坏死因子(TNF-α)、白介素-6(IL-6)和肱动脉内皮功能的影响。方法48例慢性心衰患者(NYHA分级Ⅱ～Ⅳ级)随机分成血脂康治疗组(n=24)和对照组(n=24)。2组均遵循慢性心力衰竭治疗指南给予常规治疗,治疗组加用血脂康0.6mg2次/d,共8周。检测治疗前后血清TNF-α、IL-6水平和肱动脉内皮功能。结果血脂康治疗组的血清TNF-α和IL-6水平,在血脂康治疗组明显下降(t=9.09,P<0.01;t=10.09,P<0.01),且与对照组比较差异显著(F=17.13,P<0.01;F=13.32,P<0.05)。肱动脉内皮依赖性血管舒张功能在血脂康治疗组明显提高(t=-5.7,P<0.01),且与对照组比较差异显著(F=13.31,P<0.05)。结论血脂康治疗有助于改善正常胆固醇水平慢性心力衰竭患者内皮依赖性血管舒张功能和抑制炎症过程。
Objective To observe the effect of Xuezhikang short-term treatment on serum tumor necrosis factor (TNF-α), interleukin-6 (IL-6) and brachial artery endothelial function in patients with chronic heart failure with normal cholesterol level. Methods 48 patients with chronic heart failure (NYHA class Ⅱ ~ Ⅳ grade) were randomly divided into Xuezhikang treatment group (n = 24) and control group (n = 24). Both groups were given conventional treatment of chronic heart failure guidelines, the treatment group plus Xuezhikang 0.6mg2 times / d, a total of 8 weeks. Serum TNF-α, IL-6 levels and brachial artery endothelial function were measured before and after treatment. Results Serum levels of TNF-α and IL-6 in Xuezhikang treatment group were significantly decreased in Xuezhikang treatment group (t = 9.09, P <0.01; t = 10.09, P <0.01), and were significantly different from those in control group = 17.13, P <0.01; F = 13.32, P <0.05). Endothelium-dependent vasodilatory function of brachial artery was significantly increased in Xuezhikang treatment group (t = -5.7, P <0.01), and there was significant difference compared with control group (F = 13.31, P <0.05). Conclusion Xuezhikang treatment can improve endothelium-dependent vasodilatation and suppress inflammation in patients with chronic heart failure with normal cholesterol level.